Genetic Study of Schizophrenia

This study is currently recruiting participants.
Verified August 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001486
First received: November 3, 1999
Last updated: March 14, 2014
Last verified: August 2013

November 3, 1999
March 14, 2014
June 1995
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001486 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Study of Schizophrenia
A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings

This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.

Objective: Schizophrenia is a complex genetic disorder which likely involves many genes each producing a slight increase in risk. Finding weak-acting genes in complex genetic disorders has been challenging and will likely require a number of approaches and large clinical samples. Several strategies have emerged recently that appear to markedly improve the power of genetic studies for detecting such genes. These include using association (rather than linkage) and using intermediate phenotypes in addition to DMS-IV diagnosis.

Study Population: We propose to take advantage of these techniques by studying quantitative traits related to schizophrenia in patients, siblings, and controls.

Design: We will employ an association design, rather than linkage. Traits will include quantifiable neurobiological variables that have been implicated previously as possible phenotypes related to schizophrenia. These include tests of attention and cognition, and a variety of parameters using brain imaging and magnetoencephalography.

Outcome Measure: We will use several statistical methods to show that specific genetic polymorphisms affect these phenotypes, including case control and family based association studies.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Psychotic Disorder
  • Schizoaffective Disorder
  • Schizophrenia
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
6150
Not Provided
Not Provided
  • INCLUSION/EXCLUSION CRITERIA:

Inclusion criteria for Siblings (probands and unaffected siblings):

  • Probands must have a DSM IV-R diagnosis of schizophrenia,schizoaffective disorder, psychosis N.O.S. or schizophreniform disorder.
  • Probands and Siblings must be between the ages of 18 and 55
  • Probands and Siblings must be free of major medical illnesses, but may have controlled hypertension, thyroid disease, or diabetes.
  • Probands and Siblings who do not have capacity to provide consent and are under guardianship can participate in the study if the guardian signs the informed consent and the research subject provides their written assent. A DPA is not utilized in this study.
  • Probands should be fluent in English language by age 5 due to specific requirements related to neurocognitive testing.

Exclusion Criteria for Siblings (probands and unaffected siblings):

  • Seizure disorder, mental retardation, organic brain damage or other neurological disease.
  • Previous history of illicit drug or alcohol abuse for five years or more.
  • Head trauma with loss of consciousness over 5 minutes from all but genetic sampling.
  • Documented metal in the body, e.g. from fixed dental bridges, orthodontia braces, IUDs containing metal or surgical screws.
  • Weight and height dimensions that result in size exceeding the capability of the MRI bore circumference is exclusionary.
  • Chemotherapy.

Siblings who do not qualify for the 2-day or 1-day study, may participate in the limited phenotyping arm in which only a psychiatric interview and a blood draw for genetic analysis (SCID-DNA) will be performed, case control analysis or be included as part of a trio (one parent, one sibling, one patient) to study genetic transmission from parents to offsprings.. All parents are eligible for the study.

Healthy Controls Inclusion Criteria:

To be eligible for this research study, healthy volunteers must be:

  • between the ages of 18 and 55
  • fluent in English language by age 5 due to specific requirements related to neurocognitive testing.

Healthy Controls Exclusion Criteria:

They will not be eligible if:

  • They have history of DSM IV-R psychiatric diagnosis or severe chronic medical illness at the time of the study.
  • If they have abused illicit drugs, prescription drugs or alcohol for over 5 years per DSM IV R criteria for substance abuse.
  • They may not be eligible for the 2-day or 1-day study if they have a first-degree relative with history of schizophrenia spectrum disorders. However, they may be included in the SCID_DNA or case control analyses..
  • Documented presence of metal such as orthodontia braces, surgical screws or IUD of metal composition.
  • Healthy volunteers must be free of learning disabilities.
Both
18 Years and older
Yes
Contact: Karen Bartholomew, L.C.S.W. (301) 496-4304 bartholk@intra.nimh.nih.gov
United States
 
NCT00001486
950150, 95-M-0150
Not Provided
Not Provided
National Institute of Mental Health (NIMH)
Not Provided
Principal Investigator: Karen F Berman, M.D. National Institute of Mental Health (NIMH)
National Institutes of Health Clinical Center (CC)
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP